Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management
AbstractCirculating tumoral DNA (ctDNA), commonly named “liquid biopsy”, has emerged as a new promising noninvasive tool to detect biomarker in several cancers including lung cancer. Applications involving molecular analysis of ctDNA in lung cancer have increased and encompass diagnosis, response to treatment, acquired resistance and prognosis prediction, while bypassing the problem of tumor heterogeneity. ctDNA may then help perform dynamic genetic surveillance in the era of precision medicine through indirect tumoral genomic information determination. The aims of this review were to examine the recent technical developments that allowed the detection of genetic alterations of ctDNA in lung cancer. Furthermore, we explored clinical applications in patients with lung cancer including treatment efficiency monitoring, acquired therapy resistance mechanisms and prognosis value. View Full-Text
Share & Cite This Article
Vendrell, J.A.; Mau-Them, F.T.; Béganton, B.; Godreuil, S.; Coopman, P.; Solassol, J. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. Int. J. Mol. Sci. 2017, 18, 264.
Vendrell JA, Mau-Them FT, Béganton B, Godreuil S, Coopman P, Solassol J. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. International Journal of Molecular Sciences. 2017; 18(2):264.Chicago/Turabian Style
Vendrell, Julie A.; Mau-Them, Frédéric T.; Béganton, Benoît; Godreuil, Sylvain; Coopman, Peter; Solassol, Jérôme. 2017. "Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management." Int. J. Mol. Sci. 18, no. 2: 264.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.